Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 3/20 | 0.47 |
| ▸ | FLT4 | P35916 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.43 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.42 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.42 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL653805 | 0.74 | FLT1 (0.77) | KDM4EHPGDEGFRFLT1FLT4 | |
| SCHEMBL10765828 | 0.74 | KDM4E (0.72) | KDM4EHPGDEGFRFLT1FLT4 | |
| SCHEMBL7318528 | 0.72 | PTGS2 (0.57) | KDM4EHPGDEGFRFLT1FLT4 | |
| SCHEMBL3535940 | 0.72 | PTGER4 (0.58) | KDM4EHPGDEGFRFLT1FLT4 | |
| SCHEMBL473470 | 0.71 | KDM4E (0.46) | KDM4EHPGDPOLBKMT2A | |
| SCHEMBL1412654 | 0.71 | POLB (0.71) | KDM4EHPGDEGFRFLT1FLT4 | |
| SCHEMBL209632 | 0.69 | DHFR (0.66) | KDM4EHPGDPOLBPTGS2PTGS1 | |
| SCHEMBL10931933 | 0.69 | CA2 (0.60) | KDM4EHPGDEGFRFLT1FLT4 | |
| SCHEMBL453442 | 0.69 | CA2 (0.60) | KDM4EHPGDEGFRFLT1FLT4 | |
| SCHEMBL8721449 | 0.69 | KDM4E (0.64) | KDM4EHPGDEGFRFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603893-B1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-05-21 | — | — | EP | claimed |
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-7528157-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7507754-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-03-24 | — | — | US | disclosed |
| EP-1603893-B1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-05-21 | — | — | EP | disclosed |
| US-20080039502-A1 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-05-31 | — | — | US | disclosed |
| US-7196089-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| EP-1603893-A1 | EP4 RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20040192767-A1 | EP4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
| WO-2004067524-A1 | EP4 RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, NR4A2 | KDM4E 1843/4885HPGD 618/4885EGFR 366/4885 |
| US-20040192767-A1 | EP4 receptor antagonists | PTGER4, PTGER1, NR4A1 | KDM4E 1072/4885HPGD 621/4885EGFR 422/4885 |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, PTGER1 | KDM4E 1890/4885HPGD 628/4885EGFR 368/4885 |
| US-20080039502-A1 | EP4 receptor antagonists | PTGER4, NR4A1, PTGER1 | KDM4E 2022/4885HPGD 645/4885EGFR 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.